Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway

Xuan Wei; Juanjuan Shi; Qianhan Lin; Xiaoxue Ma; Yingxin Pang; Hongluan Mao; Rui Li; Wei Lu; Yu Wang; Peishu Liu

doi:10.3389/fonc.2021.742374

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway

Front Oncol. 2021 Sep 7:11:742374. doi: 10.3389/fonc.2021.742374. eCollection 2021.

Authors

Xuan Wei^{1

2

3}, Juanjuan Shi⁴, Qianhan Lin^{1

2

3}, Xiaoxue Ma^{1

2

3}, Yingxin Pang^{1

2

3}, Hongluan Mao^{1

2

3}, Rui Li^{1

2

3}, Wei Lu^{1

2

3}, Yu Wang^{1

2

3}, Peishu Liu^{1

2

3}

Affiliations

¹ Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.
² Key Laboratory of Gynecology Oncology of Shandong Province, Qilu Hospital of Shandong University, Jinan, China.
³ Shandong Engineering Laboratory for Urogynecology, Qilu Hospital of Shandong University, Jinan, China.
⁴ Department of Gynecology and Obstetrics, Affiliated Tengzhou Center People's Hospital of Jining Medical University, Tengzhou, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.642229.].

Keywords: ACLY; AMPK-ROS pathway; PI3K-AKT pathway; cisplatin resistance; ovarian cancer.

Publication types

Published Erratum